Pharmacy institutes to mandate use of mobile app for patient safety: IPC

Mobile Online
Picture: Pixabay

Last Updated on November 1, 2019 by The Health Master

As part of its ongoing sensitisation programme on pharmacovigilance methods for reporting adverse events, the Indian Pharmacopoeia Commission (IPC) has recommended to pharmacy institutes to mandate use of PvPI-ADR mobile application by the students for reporting adverse drug reactions (ADRs) to promote patient safety.

Through this mobile application named “ADR PvPI” Android mobile app, related images of ADR and lab investigation reports can be attached in a user-friendly manner for clinical assessment and signal detection as part of pharmacovigilance.

The mobile application which has been developed keeping in mind the patients, consumers and healthcare professionals is available online for stakeholders.

IPC, the National Co-ordinating Centre (NCC) for Pharmacovigilance Programme of India (PvPI) has developed the android mobile app which empowers all the healthcare professionals and consumers for ADR reporting.

IPC is an autonomous institution of the ministry of health and family welfare created to set standards of drugs in the country. The mobile application for ADR reporting has been developed to also have administrative control of data with IPC, NCC-PvPI.

This will empower all the healthcare professionals and consumers for ADR reporting with features like supports source document and image attachment, healthcare professionals as well as consumer reporting, XML generation and auto filling of report details to save time.

This comes at a time when the Pharmacy Council of India (PCI) has also directed all pharmacy and healthcare institutions across the country to report ADRs to the existing 270 ADR Monitoring Centres (AMCs) as part of PvPI.

PvPI which was launched by the Union health ministry to report ADRs towards patients safety has been rapidly growing since its inception in April 2011.

Meanwhile, IPC has also been recognised as the WHO collaboration centre for pharmacovigilance in public health programmes and regulatory services.

An ADR is serious when the outcome is death, life threatening, hospitalisation (initial or prolonged), disability (significant, persistent or permanent), congenital anomaly and requires intervention to prevent permanent impairment or damage.

Having generated over three lakh ADR data as part of PvPI ever since its inception in 2011, IPC has set a mandate to set up a total of 300 AMCs by 2020 with focus on North Eastern (NE) states.

IPC has also been assigned to update information on ADRs that is being reported in India from across all its centres through Vigiflow software to the Uppsala Monitoring Centre (UMC) in Sweden, which is WHO’s collaborating centre for international drug monitoring.